Navigation Links
Varian Medical Systems to Exhibit X-Ray Tubes and Flat Panel Detector Technology Enhancements to Improve Digital Imaging at the ECR Annual Meeting
Date:2/29/2012

SALT LAKE CITY, Feb. 29, 2012 /PRNewswire/ -- ECR Booth #313/Expo C -- Varian Medical Systems, Inc.  (NYSE: VAR), will exhibit X-ray tubes and PaxScan® digital image detectors for fluoroscopy, angiography, cardiology and cone-beam CT imaging at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, from March 1- 5, 2012.   

"This year our exhibit reflects our dedication to continuous product improvement," said Stephen Kimmel, vice president of Sales and Marketing for Varian X-Ray Products.  "We've responded to the industry's need for advanced digital imaging solutions with revolutionary new designs of PaxPower™ X-ray tubes and a new generation of our PaxScan® line of image detectors designed to improve image quality and increase patient throughput."

The products to be highlighted at ECR are:

  • PaxScan® 1515DX – a mid-size CBCT and panoramic imaging panel using Varian's new DX technology, a proprietary, state of the art 6th generation architecture, featuring increased frame rates, improved low dose imaging and 16-bit data acquisition.  The panel is suitable for use in mini C-arm applications and is also well suited for dental and industrial applications.   
  • PaxScan® 4336X – a cassette sized flat panel detector designed with low noise electronics, 2.8 second acquisition time, internal shock event recorder and weighing only 3.1kg. The detector has 16-bit data acquisition and is available with or without handles.  
  • PaxScan® 4343CB  - a flat panel detector developed for applications in R&F, surgical, ENT, oncology and orthopedics.  The large field of view panel features multiple sensitivity ranges, extended dynamic range modes and a 139 µm pixel size for high quality radiography. 
  • PaxPower™ FP 2250 - an X-ray tube optimized for high throughput interventional procedures on systems including portable surgical CT.  The compact tube platforms were designed with higher heat dissipation which allows for higher patient throughput.
  • PaxPower™ M-1500 - Varian's first X-ray tube developed specifically for advanced mammography applications such as tomosynthesis and CT.  The M-1500 provides exceptional performance in a space efficient design allowing high quality imaging in the chest wall region.  

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 5,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:
Elaine Rebele, Varian Medical Systems
801-978-5715   elaine.rebele@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby ... America, today announced it would be offering some it’s exclusive product line to ... crafting quality and unique baby clothing/feeding products, will team up with AMAZON to ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in persons with a specific LRRK2 mutation, according to a study released today ... have provided evidence of a link between pesticides and incidence of sporadic PD ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... it is so critically important that we all are aware of our options ... Mediaplanet is proud to announce the launch of its newest edition of "Vision ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
Breaking Medicine News(10 mins):